HCP Inc. upgraded to Buy from Hold at Jefferies Jefferies upgraded HCP Inc. citing valuation and upside potential from accretive deal activity. The firm lowered its price target for shares to $41 from $43.
News For HCP From The Last 14 Days
Check below for free stories on HCP the last two weeks.
Brookdale Senior Living weakness a buying opportunity, says Stifel Stifel thinks Brookdale's (BKD) new joint venture with HCP (HCP) will be viewed positively, since it is accretive. The firm reiterates a $38 price target and Buy rating on Brookdale.